Moreover, as was demonstrated in in vivo metastatic breast cancer xenograft model, fisetin reduced lung metastasis and modulated the changes in the expression of EMT molecules and PTEN/Akt/GSK-3β in a similar way as in the in vitro model [83]. Here, GSK3B is linked to breast carcinoma.